NAYA Biosciences merges with INVO Bioscience, creating a combined oncology, autoimmune, and fertility portfolio.

INVO Bioscience and NAYA Biosciences have merged, forming a new company named NAYA Biosciences (NASDAQ: NAYA). This merger aims to enhance patient access to innovative treatments for oncology and autoimmune diseases, while maintaining the existing revenue-generating fertility business. The combined entity will broaden its portfolio to include clinical-stage assets across fertility, oncology, and autoimmune sectors.

October 14, 2024
6 Articles

Further Reading